| Identification | Back Directory | [Name]
SR7826 | [CAS]
1219728-20-7 | [Synonyms]
SR7826
N-(2-Hydroxyethyl)-N'-[4,5-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-yl)phenyl]-N-phenylurea
Urea, N-(2-hydroxyethyl)-N'-[4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]-N-phenyl- | [Molecular Formula]
C22H21N5O2 | [MDL Number]
MFCD29081182 | [MOL File]
1219728-20-7.mol | [Molecular Weight]
387.43 |
| Chemical Properties | Back Directory | [density ]
1.369±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
12.34±0.50(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
SR 7826 is used in the preparation of bis-aryl urea derivatives as potent and selective LIM kinase inhibitors. | [in vivo]
SR7826 (10 mg/kg; oral gavage; once daily; for 11 days; hAPPJ20 mice) treatment significantly reduces the phosphorylation of cofilin at Ser3. SR7826 also increases both apical and basal thin spine density significantly in hAPPJ20 mice over mock-treated animals[2].
The plasma pharmacokinetics studies on rats are investigated. After intravenous injection, the PK properties of SR7826 (compound 18b; 1mg/kg) with a Cl of 5.2 mL/min/kg, a T1/2 of 2.2h, an AUC of 8.4 μM*h and a Cmax of 7.7 μM, and has 36% oral bioavailability in rats (oral administration; 2mg/kg)[1]. | Animal Model: | hAPPJ20 mice (6-mouth-old)[2] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; once daily; for 11 days | | Result: | Significantly reduced the phosphorylation of cofilin at Ser3, a LIMK1 substrate.
|
| [IC 50]
LIMK1: 43 nM (IC50); ROCKI: 5536 nM (IC50); ROCKII: 6565 nM (IC50) | [storage]
Store at +4°C |
|
|